



PRESS RELEASE

Berlin, 31 January 2017

PROBIOTA 2017: Latest Findings in Bacteria Research

International science congress to take place in Berlin for the first time

One year ago, the German Federal Ministry of Education and Research (BMBF) approved funding to Organobalance for the research project GOBI ("Good Bacteria and Bioactives in Industry") which has Evonik Nutrition & Care GmbH and Bionorica SE as partners. Here, scientists research microorganisms for their beneficial effects to be further used in the feed, health care, and pharmaceutical industries.

Researchers from Organobalance will present preliminary results of their analyses during the international PROBIOTA convention, which will take place for the first time in Berlin on 1-3 February. It is recognised as one of the leading conferences for the probiotics-focused food and pharma industries and on the impact of bacteria on human and animal health.

Based on laboratory findings with lactic acid bacteria, Organobalance will present the latest scientific evidences of the importance of beneficial bacteria for intestinal health. The lactic acid bacteria were taken from the company's own collection of several thousand strains.

"We want to study the positive impact of healthy bacteria, and showcase some of the resulting alternatives for promoting human well-being", emphasised CEO Prof. Dr. Christine Lang prior to PROBIOTA. In recent years, we had seen a tremendous increase in the research into the interactions between microorganisms and humans or animals. Some important insights have already been made. "Based on these, we are now able to create a new generation of alternative biological agents to be used for a healthy nutrition," Ms. Lang continued.

The GOBI research project is scheduled to run for a total of six years. This is the first time that interim results are presented.

About Organobalance:

Organobalance GmbH is a biotechnology research and development company with facilities in Berlin and Flensburg. Founded in 2001, the firm develops and markets products based on probiotic bacteria cultures as well as yeast production strains for use in industrial biotechnology. One of its best-known products is Pylopass™, a natural agent against *Helicobacter pylori*, a stomach bacterium. Among the company's German and international customers are clients from the food, cosmetics, feed, agriculture, and pharmaceutical industries. The company owns an extensive collection of yeast and lactobacillus cultures, some of which date back to the 1920s. Christine Lang, the company's Managing Director, is also a Professor of Microbiology and Molecular Genetics at the TU Berlin and has received several business awards. She is chair of the German Bioeconomy Council. In September 2016, Organobalance was acquired by the Danish company Novozymes A/S.



For further information:
ORGANO BALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin, Germany
Fon +49 (0) 30 46307 200
Fax +49 (0) 30 46307 210
www.organobalance.com